Abstract — Aims: To measure the effect of community nurse follow-up on abstinence and retention rates in the outpatient treatment of alcohol-dependent patients treated with acamprosate. Methods: Recently detoxified alcohol-dependent patients were prescribed acamprosate for 26 weeks and randomized to either physician-only follow-up, or physician plus regular visits from a community nurse. Drinking behaviour in the next 26 weeks was assessed at monthly visits to non-blind clinicians. Results: The cumulative abstinence duration proportion (CADP) was significantly longer in (P = 0.03) the subjects who had received community nurse support (0.57) than in those who had not (0.39). This might, in part, be an artefact of the higher retention rate am...
Naltrexone can help prevent relapse in recently detoxified patients with alcohol use disorder. The e...
To assess the effectiveness of pharmacotherapy with acamprosate in alcohol-dependent patients treate...
Abstract — Aims: To compare treatment outcomes amongst patients offered pharmacotherapy with either ...
Aims: To measure the effect of community nurse follow-up on abstinence and retention rates in the ou...
Open label Cohort of Alocholic patients treated with acamprosate, and randomized to nurse accompanie...
An assessment of the efficacy of treatment with acamprosate was, therefore, undertaken using meta-an...
Objective: The relapse prevention medication acamprosate has been recently introduced to the Austral...
Data on patients' alcohol consumption from 15 placebo-controlled treatment studies (n = 3309) were e...
Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A ...
Objective. To examine whether the addition of acamprosate to Cognitive Behavioural Therapy (CBT) out...
We compared effects of the standard 2 g dose (n=258) and an exploratory 3 g dose of acamprosate (n=8...
Background: The aim of this study is to assess the influence of early and late compliance of acampro...
Treatment with acamprosate is a valid tool to complement psychotherapy as it does not cause addictio...
Abstract — Standard treatment for alcohol abuse may include pharmacotherapy to alleviate withdrawal ...
Impact of active follow-up on abstinence in alcohol-dependent patients treated with acamprosate. Res...
Naltrexone can help prevent relapse in recently detoxified patients with alcohol use disorder. The e...
To assess the effectiveness of pharmacotherapy with acamprosate in alcohol-dependent patients treate...
Abstract — Aims: To compare treatment outcomes amongst patients offered pharmacotherapy with either ...
Aims: To measure the effect of community nurse follow-up on abstinence and retention rates in the ou...
Open label Cohort of Alocholic patients treated with acamprosate, and randomized to nurse accompanie...
An assessment of the efficacy of treatment with acamprosate was, therefore, undertaken using meta-an...
Objective: The relapse prevention medication acamprosate has been recently introduced to the Austral...
Data on patients' alcohol consumption from 15 placebo-controlled treatment studies (n = 3309) were e...
Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A ...
Objective. To examine whether the addition of acamprosate to Cognitive Behavioural Therapy (CBT) out...
We compared effects of the standard 2 g dose (n=258) and an exploratory 3 g dose of acamprosate (n=8...
Background: The aim of this study is to assess the influence of early and late compliance of acampro...
Treatment with acamprosate is a valid tool to complement psychotherapy as it does not cause addictio...
Abstract — Standard treatment for alcohol abuse may include pharmacotherapy to alleviate withdrawal ...
Impact of active follow-up on abstinence in alcohol-dependent patients treated with acamprosate. Res...
Naltrexone can help prevent relapse in recently detoxified patients with alcohol use disorder. The e...
To assess the effectiveness of pharmacotherapy with acamprosate in alcohol-dependent patients treate...
Abstract — Aims: To compare treatment outcomes amongst patients offered pharmacotherapy with either ...